Journal of Biomolecular Screening

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, M. X.
Right arrow Articles by Carte, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, M. X.
Right arrow Articles by Carte, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Biomolecular Screening, Vol. 9, No. 5, 427-433 (2004)
DOI: 10.1177/1087057104263913

Identification of Novel Small-Molecule Inhibitors for Human Transketolase by High-Throughput Screening with Fluorescent Intensity (FLINT) Assay

Mark X. Du

S*BIO, Singapore

Janet Sim

S*BIO, Singapore

Lijuan Fang

S*BIO, Singapore

Zheng Yin

S*BIO, Singapore

Sean Koh

S*BIO, Singapore

Jennifer Stratton

Chiron Corporation, Emeryville, California, Rinat Neuroscience, Palo Alto, California

Jaume Pons

Chiron Corporation, Emeryville, California, Rinat Neuroscience, Palo Alto, California

John Jian-Xin Wang

Chiron Corporation, Emeryville, California

Brad Carte

S*BIO, Singapore

The metabolic enzyme transketolase (TK) plays a crucial role in tumor cell nucleic acid synthesis, using glucose through the elevated nonoxidative pentose phosphate pathway (PPP). Identification of inhibitors specifically targeting TK and preventing the nonoxidative PPP from generating the RNA ribose precursor, ribose-5-phosphate, provides a novel approach for developing effective anticancer therapeutic agents. The full-length human transketolase gene was cloned and expressed in Escherichia coli and the recombinant human transketolase protein purified to homogeneity. A fluorescent intensity (FLINT) assay was developed and optimized. Library compounds were screened in a high-throughput screening (HTS) campaign using the FLINT assay. Fifty-four initial hits were identified. Among them, 2 scaffolds with high selectivity, ideal physiochemical properties, and low molecular weight were selected for lead optimization studies. These compounds specifically inhibited in vitro TK enzyme activity and suppressed tumor cell proliferation in at least 3 cancer cell lines: SW620, LS174T, and MIA PaCa-2. Identification of these active scaffolds represents a good starting point for development of drugs specifically targeting TK and the nonoxidative PPP for cancer therapy.

Key Words: transketolase • nonoxidative PPP • FLINT assay • HTS • small-molecule inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
S. Vanharanta, P. J. Pollard, H. J. Lehtonen, P. Laiho, J. Sjoberg, A. Leminen, K. Aittomaki, J. Arola, M. Kruhoffer, T. F. Orntoft, et al.
Distinct expression profile in fumarate-hydratase-deficient uterine fibroids
Hum. Mol. Genet., January 1, 2006; 15(1): 97 - 103.
[Abstract] [Full Text] [PDF]